MDM2 and cancer: A potential limitation to this strategy comes from the observation that p53 reactivation via MDM2-antagonists such as Nutlin-3 not necessarily cause apoptosis in cancer cells, but it may also determine a transient growth inhibition depending on the cell and molecular context (Rinaldo et al., 2009), with obvious consequences on its possibility to eradicate cancer.